2 results
Approved WMORecruiting
Monotherapy (Parts A, B*, D, E, F and G)Primary Objectives - Evaluate the safety and tolerability of Tarlatamab - Part A only: Determine the MTD or RP2D of Tarlatamab Secondary Objectives• Evaluate preliminary anti-tumor activity of Tarlatamab •…
Approved WMORecruiting
To compare the progression free survival and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.